Trial Profile
A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Ciclosporin; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CONVERT
- Sponsors Wyeth
- 17 Mar 2020 Results pooled analysis from the data of 3 clinical trials of Sirolimus assessing rates of TEAEs, serious AEs (SAEs), and discontinuations, published in the Transplantation Proceedings
- 10 Apr 2014 Data cleaning project 4: Calcineurin inhibitors deleted from descriptors.
- 18 May 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.